


Figure S6 Letemovir exposure at steady-state: (a) AUC_{ss} at steady-state in participants with rich vs. sparse PK sampling in HSCT recipients (phase III model); (b) comparison of within-subject geometric mean C_{trough} to simulated C_{trough} using model including only between-subject variation.



Boxes show the median and upper and lower quartiles (25% and 75%) of the data; whiskers contain 100% of the data, except for statistical outliers.

AUC_{ss} , area under the concentration-time curve from 0 to 24 hours postdose at steady-state; C_{trough} , 100-fold difference in minimum concentration; HSCT, allogeneic hematopoietic stem cell transplant; PK, pharmacokinetic.